An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)

Roche

Status: Completed

Conditions: Ovarian Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01863693

ML28570

Details and patient eligibility

About

This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in routine clinical practice. Eligible patients will be followed for approximately 15 months.

Enrollment: 300 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer not previously treated with chemotherapy
• Initiating Avastin in combination with chemotherapy

Exclusion criteria

• Contraindications, warnings and precautions for use as specified in the Avastin Summary of Product Characteristics

Trial design

300 participants in 1 patient group

Cohort